Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 501–600 of 1,001
Gutiérrez‐Chico, J. L., & Mehilli, J. (2013) · Drugs · doi:10.1007/s40265-013-0135-y · Cited by 24
Advances in the diagnosis and management of acute pulmonary embolism
den Exter, P. L., van der Hulle, T., Klok, F. A., & Huisman, M. V. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50002-3 · Cited by 28
“In the Hokusai study, edoxaban (60 mg once daily) was compared to warfarin in 3319 PE patients out of a total of 8240 VTE patients [77].”
MethodDevelopments in the management and treatment of pulmonary embolism
Limbrey, R., & Howard, L. (2015) · European Respiratory Review · doi:10.1183/16000617.00006614 · Cited by 28
Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics
Mohammad, I., Korkis, B., & Garwood, C. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1991 · Cited by 29
Robertson, L., Yeoh, S. E., & Ramli, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011088.pub2 · Cited by 29
López-Núñez, J. J., Pérez-Andrés, R., Micco, P. D., Schellong, S., Cuervo, C. G., Sahuquillo, J., Ciammaichella, M. M., Morales, M., Bosevski, M., Monréal, M., et al. (2019) · TH Open · doi:10.1055/s-0039-1683970 · Cited by 25
Caterina, R. D., Agnelli, G., Laeis, P., Unverdorben, M., Rauer, H., Wang, C., Nakamura, M., Chiu, K., Reimitz, P., Koretsune, Y., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23279 · Cited by 24
“significantly fewer major and clinically relevant nonmajor bleeding events.(5) However, there is little data on the safety and effective-”
BackgroundRacial and Ethnic Differences in Response to Anticoagulation: A Review of the Literature
Gibson, C. M., & Yuet, W. C. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019894142 · Cited by 25
How I treat obese patients with oral anticoagulants
Wang, T., & Carrier, M. (2020) · Blood · doi:10.1182/blood.2019003528 · Cited by 29
Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib
Casavecchia, G., Galderisi, M., Novo, G., Gravina, M., Santoro, C., Agricola, E., Capalbo, S. F., Zicchino, S., Cameli, M., Gennaro, L. D., et al. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09926-y · Cited by 25
“Although some recent experiences with novel anticoagulants (NOACs) edoxaban [26] and rivaroxaban [27] have been reported with successful results, further studies are needed to finally promote their use in this setting.”
BackgroundCerdà, P., Becattini, C., Iriarte, A., Cortés-Hernández, J., Corbella, X., & Riera‐Mestre, A. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.012 · Cited by 25
Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis
Oldham, M., Palkimas, S., & Hedrick, A. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211047433 · Cited by 25
“001 NASH, n (%) 6 (9) 7 (22) NS HCV, n (%) 8 (12) 3 (10) NS Cardiac cirrhosis, n (%) 5 (7) 5 (16) NS HCC, n (%) 6 (9) 0 0.”
A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
Güler, E., Güler, G. B., Demır, G. G., & Hatipoğlu, S. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6532 · Cited by 26
“However, it may be rational to use drugs with lower renal clearance (Rivaroxaban 66%, Apixaban 27%, Edoxaban 35%) (45) in these patients because of increased creatinine clearance.”
BackgroundErratum: Balancing ischaemia and bleeding risks with novel oral anticoagulants
Baber, U., Mastoris, I., & Mehran, R. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.204 · Cited by 24
Dobesh, P. P., & Fanikos, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0301-x · Cited by 24
Barbar, S., Milan, M., Campello, E., Spiezia, L., Piovella, C., Pesavento, R., & Prandoni, P. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-04-0396 · Cited by 26
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
Milling, T. J., & Kaatz, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.009 · Cited by 26
Roetker, N. S., Lutsey, P. L., Zakai, N. A., Alonso, Á., Adam, T. J., & MacLehose, R. F. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668521 · Cited by 23
Dentali, F., Minno, M. N. D. D., Gianni, M., Ambrosino, P., Squizzato, A., & Ageno, W. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1249-x · Cited by 26
“Six studies [14–19] for a total of 27,023 patients with acute VTE were included in the analysis.”
BackgroundMethodResultInfluentialVenous thromboembolism mortality and trends in older US adults, 2011–2019
Giorgio, K., Walker, R. F., MacLehose, R. F., Herrera, D. A., Wang, W., Alonso, Á., Zakai, N. A., & Lutsey, P. L. (2023) · American Journal of Hematology · doi:10.1002/ajh.26996 · Cited by 25
Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism
Brunton, N. E., McBane, R. D., Casanegra, A. I., Houghton, D. E., Balanescu, D. V., Ahmad, S. R., Caples, S. M., Motiei, A., & Henkin, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010257 · Cited by 27
“There was a reduction in VTE recurrence for patients with RV dysfunction treated with edoxaban compared to warfarin [47].”
BackgroundEdoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials
Plitt, A., & Giugliano, R. P. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414523675 · Cited by 23
“98).(37) The rates of major bleeding were also significantly lower in the edoxaban group.”
BackgroundMethodInfluentialChanging Practice of Anticoagulation: Will Target-Specific Anticoagulants Replace Warfarin?
Arepally, G. M., & Ortel, T. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024633 · Cited by 27
Noble, S., & Sui, J. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30115-3 · Cited by 24
Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension
Gabriel, L., Delavenne, X., Bedouch, P., Khouatra, C., Bouvaist, H., Cordier, J.-F., Mornex, J., Pison, C. M., Cottin, V., & Bertoletti, L. (2016) · Respiration · doi:10.1159/000445122 · Cited by 23
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide
Shatzel, J. J., Daughety, M. M., Olson, S. R., Beer, T. M., & DeLoughery, T. G. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022004 · Cited by 23
“004 for superiority).(28,29) Edoxaban appears to be less efficacious at stroke prevention in patientswith normal renal function; therefore, it contraindicated in patients with nonvalvular atrial fibrillation whose creatinine clearance is.”
BackgroundBartoli-Abdou, J., Patel, J. P., Crawshaw, J., Vadher, B., Brown, A. H., Roberts, L. N., Patel, R., Arya, R., & Auyeung, V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2017.12.021 · Cited by 24
Wik, H. S., Kahn, S. R., Eriksson, H., Morrison, D., Ghanima, W., Schulman, S., & Sandset, P. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15449 · Cited by 24
Immunotherapy in antiphospholipid syndrome
López-Pedrera, C., Aguirre, M. A., Ruiz‐Limón, P., Pérez‐Sánchez, C., Jiménez, Y., Barbarroja, N., & Cuadrado, M. J. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.06.006 · Cited by 25
Klok, F. A., Barco, S., & Konstantinides, S. (2018) · European Respiratory Journal · doi:10.1183/13993003.00077-2018 · Cited by 24
“In a subsequent study, we tested VTE-BLEED in the patients included in the HOKUSAI-VTE trial.(10) We concluded that VTE-BLEED indeed adequately identified patients at high risk for major bleeding, which occurred in 2.”
MethodAmin, A., Jing, Y., Trocio, J., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.950670 · Cited by 22
Karakasis, P., Ktenopoulos, N., Pamporis, K., Sagris, Μ., Σουλαϊδόπουλος, Σ., Gerogianni, M., Leontsinis, I., Giannakoulas, G. A., Tousoulis, D., Fragakis, N., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133784 · Cited by 26
“The same observation also applies to trials focusing on VTE, where the percentage of participants with a weight exceeding 100 kg falls between 15 and 20% [62–64].”
MethodDamman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Loffredo, L., Perri, L., Ben, M. D., Angelico, F., & Violi, F. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1171-7 · Cited by 27
“(AMPLIFY and HOKUSAI studies [24, 26]).”
BackgroundManagement of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Finks, S. W., Trujillo, T. C., & Dobesh, P. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632785 · Cited by 24
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
Brown, K. S., Zahir, H., GROSSO, M. A., Lanz, H., Mercuri, M. F., & Levy, J. H. (2016) · Critical Care · doi:10.1186/s13054-016-1422-2 · Cited by 27
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
Vandell, A. G., Walker, J. R., Brown, K. S., Zhang, G., Lin, M., GROSSO, M. A., & Mercuri, M. F. (2017) · Heart · doi:10.1136/heartjnl-2016-310901 · Cited by 22
Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism
Ghazvinian, R., Gottsäter, A., & Elf, J. L. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1607-9 · Cited by 24
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment
Schindewolf, M., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400302 · Cited by 23
Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
Kar, S., Mottamal, M., & Al‐Horani, R. A. (2020) · ChemistryOpen · doi:10.1002/open.202000277 · Cited by 23
Kim, H. Y., Chang, S., Kim, K. H., Kim, J. Y., Seo, W., Kim, H., Seo, J.-S., Shin, S., Rhee, S. J., Lee, S. H., et al. (2021) · Journal of Cardiovascular Imaging · doi:10.4250/jcvi.2021.0014 · Cited by 24
Fukasawa, T., Seki, T., Nakashima, M., & Kawakami, K. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15799 · Cited by 24
Puy, L., Forman, R., Cordonnier, C., & Sheth, K. N. (2022) · Stroke · doi:10.1161/strokeaha.122.036888 · Cited by 25
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Linnemann, B., Beyer‐Westendorf, J., Espinola–Klein, C., Mühlberg, K. S., Müller, O. J., & Klamroth, R. (2024) · Hämostaseologie · doi:10.1055/a-2178-6574 · Cited by 32
Cancer-associated thrombosis in Asia
Angchaisuksiri, P. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0110-4 · Cited by 26
Lusk, K. A., Snoga, J. L., Benitez, R. M., & Sarbacker, G. B. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017707126 · Cited by 26
“6% and a minor bleeding risk of up to 14% per year.(1-20) Dabigatran is indicated in treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), stroke prevention in nonvalvular atrial fibrillation, and prophylaxis of DVT and PE following hip replacement surgery.”
BackgroundEvaluation of direct oral anticoagulants and vitamin K antagonists in mesenteric venous thrombosis
Salim, S., Ekberg, O., Elf, J. L., Zarrouk, M., Gottsäter, A., & Acosta, S. (2018) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355518779517 · Cited by 24
Update on extended treatment for venous thromboembolism
Peñaloza-Martínez, E., Rodríguez, P. D., Proietti, M., Fernández‐Llamazares, G. S., Mendo, C. L., Álvarez-Sala, J. L., Marra, A. M., & del Toro‐Cervera, J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1538564 · Cited by 26
“The HOKUSAI-VTE study [36] (a randomized, double-blind, double-dummy trial designed to assess the efficacy and safety of edoxaban for the treatment of VTE), showed that a single daily dose of edoxaban was as effective and safer than warfarin after an initial course of heparin for 5 days (acute phase) in patients with…”
MethodBrenner, B., Hull, R. D., Arya, R., Beyer‐Westendorf, J., Douketis, J. D., Elalamy, I., Imberti, D., & Zhai, Z. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0196-6 · Cited by 26
“Some published studies, specifically the AMPLIFY trial [73] and the Hokusai-VTE trial [74], demonstrate that DOACs have similar efficacy to that of LMWHs or warfarin.”
It's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
Treatment Failures of Direct Oral Anticoagulants
Kajy, M., Mathew, A., & Ramappa, P. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001083 · Cited by 27
Valeriani, E., Porreca, E., Weitz, J. I., Schulman, S., Candeloro, M., & Nisio, M. D. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14807 · Cited by 26
Powell, M. Z., de Villers, K. T., Schwarz, K. A., Case, D. E., & Trujillo, T. C. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020952749 · Cited by 23
Ceresetto, J. M. (2016) · Clinics · doi:10.6061/clinics/2016(01)07 · Cited by 25
“The results of key studies of each of the DOACs are summarized in Table 2 (64-71).”
BackgroundUse of novel oral anticoagulant agents in venous thromboembolism
Madan, S., Shah, S., Dale, P., Partovi, S., & Parikh, S. A. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2016.11.17 · Cited by 23
“The Hokusa i -VTE inves t iga tors conducted a randomized, double-blinded, noninferiority trial that compared heparin followed by edoxaban to heparin followed by warfarin for treatment of PE, DVT, or both (Table 3) (35).”
MethodBromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
“RE-COVER [27] RE-COVER II [43] EINSTEINDVT [40] EINSTEINPE [44] AMPLIFY [45] Hokusai-VTE [28]”
MethodCohen, A. T., Berger, S. E., Milenković, D., Hill, N. R., & Lister, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.017 · Cited by 22
Merli, G. J., Hollander, J. E., Lefèbvre, P., Laliberté, F., Raut, M. K., Olson, W. H., & Pollack, C. V. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1021659 · Cited by 21
“Recently, large international trials of non-VKA oral anticoagulant (NOAC) agents, including rivaroxaban, dabigatran, apixaban, and edoxaban, have shown comparable or superior efficacy and safety to the combination of LMWH/warfarin for the treatment of DVT [1,5-8].”
BackgroundTreatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants
Lee, A. Y. Y., & Carrier, M. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50027-8 · Cited by 26
“The Hokusai-VTE trial investigating edoxaban for the treatment of VTE has included the largest number and the highest proportion of patients with cancer amongst all the NOAC VTE treatment trials [24].”
MethodNovel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions
Nakamura, M., Yamada, N., & Ito, M. (2017) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00015 · Cited by 24
Tomkowski, W. Z., Kuca, P., Urbanek, T., Chmielewski, D., Krasiński, Z., Pruszczyk, P., Windyga, J., Oszkinis, G., Jawień, A., Burakowski, J., et al. (2017) · Acta Angiologica · doi:10.5603/aa.2017.0008 · Cited by 27
“Initial anticoagulant therapy with heparin is necessary if long-term treatment with dabigatran or edoxaban is planned [21, 22, 25].”
BackgroundGroetzinger, L. M., Miller, T. J., Rivosecchi, R. M., Smith, R. E., Gladwin, M. T., & Rivera‐Lebron, B. N. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618755311 · Cited by 21
“daily life.(7,8) Clotting events were defined as new or recurrent deep venous thrombosis, PE, or another vascular event such as acute coronary syndrome or ischemic stroke.”
BackgroundInfluentialGrandoni, F., & Alberio, L. (2019) · Cancers · doi:10.3390/cancers11010046 · Cited by 23
“Edoxaban was able to demonstrate similar results than warfarin in a total of 4118 patients enrolled in the trial of the Hokusai-VTE investigators [32].”
MethodResultYamashita, Y., Yoshikawa, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.032 · Cited by 25
Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
Hayashi, T., Takatori, H., Horii, R., Nio, K., Terashima, T., Iida, N., Kitahara, M., Shimakami, T., Arai, K., Kitamura, K., et al. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1140-8 · Cited by 22
Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism
Quan, S., Smith, J. E., Wu, C. M., Koshman, S. L., Nguyen, B. V., & Bungard, T. J. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.01.011 · Cited by 22
Fankhauser, C. D., Tran, B., Pedregal, M., Ruiz-Morales, J. M., González‐Billalabeitia, E., Patrikidou, A., Amir, E., Seidel, C. A., Bokemeyer, C., Hermanns, T., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.09.017 · Cited by 21
Li, H., Yao, M., Liao, S., Chen, J., & Yu, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.597623 · Cited by 21
Review of Medical Therapies for the Management of Pulmonary Embolism
Panahi, L., Udeani, G., Horseman, M. A., Weston, J. S., Samuel, N. G., Joseph, M., Mora, A., & Bazan, D. Z. (2021) · Medicina · doi:10.3390/medicina57020110 · Cited by 27
“The trial showed that edoxaban was not inferior to warfarin but had a lower bleeding risk [36].”
BackgroundHuang, H., Peng, C. C., Lin, S., Munir, K. M., Chang, R. H., Wu, B., Liu, P. P., Hsu, J., Loh, C., & Tu, Y. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019618 · Cited by 23
Merli, G. J., Hollander, J. E., Lefèbvre, P., Laliberté, F., Raut, M. K., Germain, G., Bookhart, B., & Pollack, C. V. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1096274 · Cited by 23
Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615585991 · Cited by 20
“As real-world observational studies have shown patient populations with VTE markedly differ from those participating in clinical trials, it is important to predict medical cost differences among patients with VTE receiving different treatments in real-world settings.(6-14,17,19) The study of Lefebvre et al, from which…”
BackgroundMethodResultInfluentialYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.08.053 · Cited by 21
Kreutz, R. H., Mantovani, L. G., Haas, S. K., Monje, D., Schneider, J., Bugge, J., Gebel, M., Tamm, M., Ageno, W., & Turpie, A. G. G. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.02.010 · Cited by 24
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism
Koehl, J. L., Hayes, B. D., Al-Samkari, H. T., & Rosovsky, R. P. G. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1711731 · Cited by 21
Cardinal, R. M., D'Amico, F. J., D'Addezio, A. S., Dakers, K., & Castelli, G. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02361-8 · Cited by 20
Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms
Falanga, A., Marchetti, M., & Schieppati, F. (2021) · Hämostaseologie · doi:10.1055/a-1334-3259 · Cited by 26
Wumaier, K., Li, W., Chen, N., & Cui, J. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00319-1 · Cited by 23
Pavlovic, D., Nićiforović, D., Marković, M., & Papic, D. (2023) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231220297 · Cited by 28
“174,175 176-179 In comparison with LMWH, patients who received DOACs had a significantly reduced risk of recurrent VTE events, although there was no significant increase in major bleeding events.”
BackgroundBauersachs, R. M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.05.017 · Cited by 20
Direct oral anticoagulants: unique properties and practical approaches to management
Barnes, G. D., & Kurtz, B. (2016) · Heart · doi:10.1136/heartjnl-2015-309075 · Cited by 22
Assessing patient preferences for switching from warfarin to direct oral anticoagulants
Wright, J. N., Vazquez, S. R., Kim, K., Jones, A. E., & Witt, D. M. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01915-9 · Cited by 20
Pompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Grundtvig, J. L. G., Ovesen, C., Havsteen, I. B., Christensen, T., Gaist, D., Iversen, H. K., Kruuse, C. R., Lilja‐Cyron, A., Ægidius, K. L., Rosenbaum, S., et al. (2021) · European Stroke Journal · doi:10.1177/23969873211008770 · Cited by 22
Bădescu, M. C., Ciocoiu, M., Bădulescu, O. V., Vladeanu, M. C., Bojan, I. B., Vlad, C.-E., & Rezuș, C. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10779 · Cited by 26
“Although the incidence of those events was low in all studies (8,9,30), the VTE‐BLEED score showed a good prediction ability.”
BackgroundClinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism
Bacchus, F., & Schulman, S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303396 · Cited by 23
“Major bleeding was not statistically different, although clinically relevant nonmajor bleeding was significantly less frequent in the edoxaban group.(19)”
BackgroundResultSciascia, S., Radin, M., Schreiber, K. I., Fenoglio, R., Baldovino, S., & Roccatello, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1753-2 · Cited by 22
Pottegård, A., Grove, E. L., & Hellfritzsch, M. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4350 · Cited by 21
“Recently, another factor Xa‐inhibitor, edoxaban, has been approved as the fourth DOAC in Europe, licensed for use in atrial fibrillation(3) as well as treatment and secondary prevention of pulmonary embolism and deep vein thrombosis.(4)”
BackgroundEighty years of oral anticoagulation: Learning from history
Montinari, M. R., Minelli, S., & Caterina, R. D. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106918 · Cited by 21
Management of cancer-associated thromboembolism in vulnerable population
Laporte, S., Benhamou, Y., Bertoletti, L., Frère, C., Hanon, O., Couturaud, F., Moustafa, F., Mismetti, P., Sanchez, O., & Mahé, I. (2023) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2023.11.009 · Cited by 19
Prandoni, P. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.013 · Cited by 21
Inferior vena cava filters: current best practices
Rajasekhar, A. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1187-5 · Cited by 19
Tangelder, M. J. D., Nwachuku, C., Jaff, M. R., Baumgärtner, I., Duggal, A., Adams, G. L., Ansel, G. M., GROSSO, M. A., Mercuri, M. F., Shi, M., et al. (2015) · Journal of Endovascular Therapy · doi:10.1177/1526602815574687 · Cited by 19
“The Hokusai-VTE study involving 8292 patients with acute venous thromboembolism showed that once-daily edoxaban at a dose of 60 mg (reduced to 30 mg in selected patients) was as effective as warfarin for the prevention of recurrent symptomatic venous thromboembolism and was associated with a significantly lower rate o…”
BackgroundBeyer‐Westendorf, J., Lensing, A. W. A., Arya, R., Bounameaux, H., Cohen, A. T., Wells, P. S., Middeldorp, S., Verhamme, P. B., Hughes, R. J., Kucher, N., et al. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.11.014 · Cited by 21
“Recent randomised active-controlled trials that included over 27,000 patients have established the direct oral anticoagulants (DOACs) as efficacious and safe treatment options for patients with acute symptomatic venous thromboembolism (VTE).[1-6] With fixed dosing and no need for routine coagulation monitoring, the DO…”
BackgroundAnticoagulation Therapy and NOACs in Heart Failure
Thomas, I. C., EncisoSilva, J., Schlueter, M., & Greenberg, B. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_126 · Cited by 19
Signorelli, J., & Gandhi, A. S. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217739683 · Cited by 19
Poli, D., Antonucci, E., Bertù, L., Vignini, E., Ruocco, L. A., Mastroiacovo, D., Paparo, C., Pastori, D., Testa, S., Ageno, W., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.08.024 · Cited by 19
“The use of low-dose regimen has not been tested in the registrative trials for the use of DOACs in acute VTE patients, with the exception of Hokusai study [12].”
MethodYamashita, Y., Murata, K., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.10.029 · Cited by 20
Kim, J. H., Seo, S., Kim, K., Chang, H.-M., Ryoo, B., Yoo, C., Jeong, J. H., Lee, J. L., Im, H.-S., Jeong, H., et al. (2020) · In Vivo · doi:10.21873/invivo.11845 · Cited by 20
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.